From Healthing.ca: Canada’s healthcare system is strained. It was always strained. It was designed that way. The United States healthcare system has excess capacity. Costs are constrained by insurance companies requiring pre-approval before non-emergency interventions. [...]
From MDPI: Abstract Historically, subject matter experts and healthcare professionals have played a pivotal role in driving oncology clinical trials. Although patients have been key participants, their deliberate and active contribution to the design and [...]
From the Frontiers website: Introduction Predictive oncology, germline technologies, and adaptive seamless trials are promising advances in the treatment of lethal cancers. Yet, access to these therapies is stymied by costly research, regulatory barriers, and [...]
Dr. Dave Steward recently gave a webinar to Prostate Cancer Support Canada to answer common questions people have about cancer.
LSTN's own Dr. Dave Stewart recently released a book that answers some of of the most common, vexing questions about cancer.
From Current Oncology: "New drugs are expensive, in part due to excessive drug development costs. Governments are trying to reduce drug prices. This can delay access to effective agents. A country’s access to new drugs [...]
From the Wiley Online Library: Background Systemic therapy prolongs overall survival (OS) in advanced non-small cell lung cancer (NSCLC), but diagnostic tests, staging and molecular profiling take time, and this can delay therapy initiation. OS [...]
From Healthing: "The body responsible for pricing patented drugs in Canada — the Patented Medicine Prices Review Board (PMPRB) — has proposed changes to lower the cost of drugs, which are scheduled to come into [...]
From C.A.R.P.: "Like father, like son. In the 1970s, Trudeau senior brought in price controls to combat inflation. They failed miserably. On July 1, Trudeau junior’s government will activate new Patented Medicines Price Review Board [...]
From The Ottawa Citizen: "The federal Patented Medicines Price Review Board thinks companies would be happy to sell Canada their new drugs for much less than they get in many other 36 OECD countries. It [...]